Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

Combined biparatopic nanobody-based B cell maturation antigen chimeric antigen receptor T cell therapy and pomalidomide for relapsed or refractory multiple myeloma: In-vitro characterisation and phase 1 dose-escalation study

Jie Zhao, Linyu Li, Zhilin Gao, Shaolong He, Lifang Huang, Tao Wang, Rong Gong, Qiujuan Zhu, Xize Wang, Jia Wei, Weiwei Tian

Blood (2025) 146 (Supplement 1): 253.

https://doi.org/10.1182/blood-2025-253

Published: 2025

Journal Articles

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

Blood (2025) 146 (Supplement 1): 7546.

https://doi.org/10.1182/blood-2025-7546

Published: 2025

Journal Articles

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

Menghan Liu, Xiaoqi Qin, Weiwei Tian, Yuechen Zhang, Yanru Zhang, Lefu Huang, Wenjing Li, Jingrong Wang, Yanping Ma, Liping Su, Yan Yan, Aijun Liao, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2025-2280

Published: 2025

Journal Articles

CD19 CAR-T cell therapy in AML1-ETO positive Acute Myeloid Leukemia: A multi-omics analysis of response determinants

Anqi Zhang, Jie Zhao, Yicheng Zhang, Weiwei Tian, Wei Mu, Jia Wei

Blood (2025) 146 (Supplement 1): 6957.

https://doi.org/10.1182/blood-2025-6957

Published: 2025

Journal Articles

Enhanced efficacy and safety of optimized tandem CD19/CD20 CAR T-cell Therapy in refractory/relapsed B-cell lymphoma

Jiaqi Guo, Ang Zhang, Weiwei Tian, Xiaoxi Zhou, Xiao Zhao, Yang Cao, Shaolong He, Jie Zhao, Lihong Liu, Lifang Huang, Yicheng Zhang, Bing Liu, Jia Wei

Blood (2025) 146 (Supplement 1): 2325.

https://doi.org/10.1182/blood-2025-2325

Published: 2025

Journal Articles

Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia

Wei Mu, Anqi Zhang, Xingcheng Yang, Xiaoxi Zhou, Jie Zhao, Yicheng Zhang, Weiwei Tian, Junjie Shen, Haoyue Qin, Yingzi Zhang, Cheng Qian, Jia Wei

Blood (2025) 146 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2025-1639

Published: 2025

Journal Articles

Impact of Febrile Neutropenia on Mobilization Efficacy in Multiple Myeloma Patients and Post-Transplant Infection Risk in Lymphoma Patients: Insights from Real-World Multicenter Data

Hu Qian, Xinwei Wang, Liping Yang, Juan Peng, Jie Zhao, Shaolong He, Jin Zhao, Jiaqi Guo, Yuekun Fang, Fankai Meng, Yang Cao, Lifang Huang, Junni Wei, Liangming Ma, Li-Ping Su, Weiwei Tian, Yicheng Zhang, Jia Wei

Blood (2024) 144 (Supplement 1): 7834.

https://doi.org/10.1182/blood-2024-205222

Published: 2024

Journal Articles

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Fujing Zhang, Wei Wang, Hua Wang, Wei Wang, Aijun Liu, Weiwei Tian, Xiaoqi Qin, Zhongjun Xia, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2024-209342

Published: 2024

Journal Articles

Clinical Characteristics and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Analysis from China

Wenjing Li, Weiwei Tian, Jie Ma, Linyu Li, Zhihua Li, Guorong Gao, Lan Zhang, Lixiang Duan, Hui Geng, Jie Meng, Wen Gao

Blood (2024) 144 (Supplement 1): 6976.

https://doi.org/10.1182/blood-2024-205575

Published: 2024

Journal Articles

Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

Jia Wei, Xiaoxi Zhou, Hui Luo, Yang Cao, Jiaqi Guo, Jie Zhao, Lifang Huang, Ang Zhang, Lihong Liu, Weiwei Tian, Yicheng Zhang

Blood (2024) 144 (Supplement 1): 3132.

https://doi.org/10.1182/blood-2024-205207

Published: 2024

Journal Articles

High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation

Blood (2024) 144 (Supplement 1): 6925.

https://doi.org/10.1182/blood-2024-205155

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

ECOG,β2-Microglobulin, Hemoglobin and Lactate Dehydrogenase Can Predict Early Grade ≥ 3 Infection Accurately in Patients with Newly Diagnosed Multiple Myeloma: A Real-World Study from China

Xinyi Lu, Xinyue Chen, Liping Yang, Qiong Yao, Jie Zhao, Shaolong He, Liangming Ma, Chunrui Li, JIA Wei, Weiwei Tian

Blood (2022) 140 (Supplement 1): 12545–12546.

https://doi.org/10.1182/blood-2022-166285

Published: 2022

Journal Articles

Hematological Disorders in Conjunction with Maxillofacial Fungal Cellulitis: A Clinical and Literature Evaluation of 5 Cases

Xinyue Chen, Xinyi Lu, Xinwei Wang, Liangming Ma, JIA Wei, Chunrui Li, Junni Wei, Weiwei Tian

Blood (2022) 140 (Supplement 1): 11203–11204.

https://doi.org/10.1182/blood-2022-168896

Published: 2022

Journal Articles

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2022) 140 (Supplement 1): 10167–10169.

https://doi.org/10.1182/blood-2022-159361

Published: 2022

Journal Articles

Design and Construction of Multi-Epitope Fusion Gene Vaccine of Wilm Tumor Gene WT1 and Stimulating Epitope of Mycobacterium Tuberculosis Heat Shock Protein 70

Weiwei Tian, Zhenhua Qiao, MD, Fang Ye

Blood (2010) 116 (21): 4713.

https://doi.org/10.1182/blood.V116.21.4713.4713

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Combined biparatopic nanobody-based B cell maturation antigen chimeric antigen receptor T cell therapy and pomalidomide for relapsed or refractory multiple myeloma: In-vitro characterisation and phase 1 dose-escalation study

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

CD19 CAR-T cell therapy in AML1-ETO positive Acute Myeloid Leukemia: A multi-omics analysis of response determinants

Enhanced efficacy and safety of optimized tandem CD19/CD20 CAR T-cell Therapy in refractory/relapsed B-cell lymphoma

Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia

Impact of Febrile Neutropenia on Mobilization Efficacy in Multiple Myeloma Patients and Post-Transplant Infection Risk in Lymphoma Patients: Insights from Real-World Multicenter Data

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Clinical Characteristics and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Analysis from China

Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

ECOG,β2-Microglobulin, Hemoglobin and Lactate Dehydrogenase Can Predict Early Grade ≥ 3 Infection Accurately in Patients with Newly Diagnosed Multiple Myeloma: A Real-World Study from China

Hematological Disorders in Conjunction with Maxillofacial Fungal Cellulitis: A Clinical and Literature Evaluation of 5 Cases

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Design and Construction of Multi-Epitope Fusion Gene Vaccine of Wilm Tumor Gene WT1 and Stimulating Epitope of Mycobacterium Tuberculosis Heat Shock Protein 70

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only